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ABSTRACT 
Introduction: Neurodegeneration resulting from pathogen invasion or tissue damage has been associated with 
activation of microglia, and exacerbated by the release of neurotoxic mediators such as pro-inflammatory cytokines, 
chemokines and reactive oxygen species. Activation of microglia stimulated by lipopolysaccharide is mediated in 
part by GSK-3 signaling molecule. Induced IL-10 expression via GSK-3 inhibition is noteworthy since IL-10 has been 
remarkably shown to suppress inflammation. Objectives: We aimed to inactivate microglia through inhibition of 
GSK-3 signaling and to determine its effects on the production of pro- and anti-inflammatory mediators. Methods: 
LPS-stimulated BV-2 cells were treated with a GSK-3 inhibitor (LiCl, NP12, SB216763 or CHIR99021). Inhibition 
of GSK-3 was determined by the phosphorylation status of GSK-3β. The effects of GSK-3 inhibition on microglial 
inflammatory response were investigated by examining various mediators and CD200R marker. Production of nitric 
oxide (NO), glutamate and pro- and anti-inflammatory cytokines were measured using flow cytometry, Griess assay, 
glutamate assay and Cytometric Bead Array (CBA) respectively. Results: GSK-3β signaling in LPS-stimulated microglia 
was blocked by GSK-3 inhibitor through increased phosphorylation at Serine 9 residue. GSK-3 inhibitors had also 
led to reducing in microglia activity via increased expression of CD200R. Inhibition of GSK-3 also diminished 
inflammatory mediators such as nitric oxide (NO), glutamate, pro-inflammatory cytokines (TNF-α and IL-6) and 
chemokine, MCP-1. Reduction of pro-inflammatory mediators by GSK-3 inhibitor was coincided with increased 
IL-10 production. Conclusions: Suppression of microglia-mediated inflammatory response was facilitated by GSK-3 
inhibition with associated increased in IL-10 production. 
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INTRODUCTION
Microglia are the resident immune cells of the CNS, 
which typically exist in a resting state and regulate 
various processes (1). Activation of microglia induced 
by various stimuli, such as lipopolysaccharide (LPS), is 
commonly accompanied by inflammatory responses to 
remove damaged cells by phagocytosis (2). Binding of 
LPS to toll-like receptor 4 (TLR4) on microglia increases 
expression of MHC class II, CD40, CD80 and CD86 and 
increases production of pro-inflammatory mediators (3). 
Chronic microglial activation could confer deleterious 
effects, which can kill neurons and other neighbouring 
cells through the release of cytotoxic inflammatory 
mediators, such as pro-inflammatory cytokines, 
proteinases and reactive oxygen species (4). Studies 
have shown that various neuropathological conditions, 
such as multiple sclerosis, Alzheimer’s disease (AD) and 
Parkinson’s disease (PD), are attributed to the activation 
of microglia (5-7).
 
Several cell surface markers have been studied 
to determine microglial activation state including 
CD200R, an inhibitory marker of macrophages (2). 
Binding of CD200R to CD200 ligand induces inhibitory 
signal to the cells, which was found to downregulate 
inflammation in diseases such as MS (8) and AD (9). 
The absence of this inhibitory signal, however, has 
been reported to contribute to the pathogenesis of 
AD (9) and also worsen the neuroinflammation in PD 
animal model (10). Upon activation, microglia releases 
abundant of nitric oxide (NO), which is important as 
defense molecule against infectious agents and regulate 
multiple processes of immune cells (11). However, 
the previous study revealed that high level of NO 
profoundly inhibits mitochondrial cytochrome oxidase, 
which leads to neuronal cell death (12, 13). This may 
be due to competition between NO and oxygen for 
cytochrome oxidase, which resulted in respiratory 
inhibition and subsequently neuronal depolarisation 
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and glutamate secretion (12). In addition, glutamate is 
the most abundant excitatory neurotransmitter in CNS, 
plays an important role in learning and memorizing 
(14). However, overproduction of glutamate may have 
detrimental effects by causing an imbalance in CNS 
homeostasis. High level of excitatory glutamate can 
also cause neuronal cell death by oligodendrocyte 
killing (15). Impairment of oligodendrocyte will lead 
to demyelination, the important hallmark of MS (16). 
Therefore, suppression of microglial activation may 
prevent the cytotoxic effects of NO and glutamate.
 
Glycogen synthase kinase (GSK-3) is a protein kinase 
that plays a role in many cellular processes (17). In 
the inflammatory processes mediated by microglial 
activation, GSK-3 has been seen to contribute to 
inflammation through the production of pro-inflammatory 
cytokines and increase cell activation and migration 
(18). Inhibition of GSK-3 through phosphorylation 
inactivates its protein kinase and negatively regulates 
the pro-inflammatory responses [19]. Previous findings 
have shown that inhibition of GSK-3 using short-
interference RNA and cells transfection with dominant-
negative GSK-3β reduced NO production, but increased 
expression of IL-10 in both BV-2 cells and primary rat 
microglia cultures (20). 
 
The chronic inflammatory process commonly 
contributes to cell damage and tissue injury. However, 
this process may be retracted by the release of the anti-
inflammatory molecule such as IL-10. IL-10 is an anti-
inflammatory cytokine produced by various cells in 
both innate and adaptive immune system, which plays 
a crucial role in disease protection and prevention 
of host damage (21). The role of IL-10 has also been 
discovered as a cytokine that controls pathogenicity 
of neuroinflammation through inhibition of Th1- and 
Th17-associated cytokines, particularly IFNγ and IL-17, 
respectively (22). In addition, the inhibitory action of 
IL-10 during inflammatory responses could also reduce 
the activation and differentiation of macrophages, B 
cells and T cells (23). In relation to GSK-3 signaling, the 
role of IL-10 has been demonstrated in the LPS-induced 
endotoxin shock animal model (24). Increased in IL-10 
production has been associated with downregulation of 
pro-inflammatory cytokines through inhibition of GSK-3 
(24). These studies have also revealed the crucial role 
of IL-10 in limiting damage by excessive inflammatory 
responses. Thus, suppression of GSK-3 activity may be a 
potential strategy to reduce the pathogenicity of the pro-
inflammatory molecules through an increase in IL-10 
production. The objectives of this study are to determine 
the effects of GSK-3 inhibition on the microglial activity, 
the production of pro-inflammatory mediators and the 
IL-10 production in the LPS-stimulated BV-2 cells.
MATERIALS AND METHODS
Antibodies and reagents
LPS from Escherichia coli strain O111:B4 and Glutamate 
assay kit were acquired from Sigma-Aldrich (St. Louis, 
MO). GSK-3 inhibitors such as Lithium Chloride (LiCl), 
SB216763, NP12 and CHIR99021 were also obtained 
from Sigma-Aldrich (St. Louis, MO). Cell culture 
medium and reagents were obtained from Invitrogen 
(Carlsbad, CA). Griess reagent was obtained from Abcam 
(Cambridge, MA). Fluorochrome conjugated anti-
mouse CD200R-PE, and Cytometric Bead Array (CBA) 
inflammation kit were obtained from Becton Dickinson 
Biosciences (San Jose, CA). Mouse monoclonal GSK-
3β and phospho-GSK-3β antibodies were purchased 
from Cell Signalling (Danvers, MA), whereas mouse 
monoclonal tubulin antibody was from Thermo Fisher 
Scientific (Waltham, MA). 
Cell culture
The BV-2 immortalised murine microglial cells was a 
generous gift from Assoc. Prof. Dr. Thameem Dheen 
(National University Singapore). Cells were maintained 
in Dulbecco Modified Eagle Medium (DMEM) (or phenol 
red-free DMEM for NO production) supplemented with 
5% fetal bovine serum (FBS), 100 U/ml penicillin, 100 
µg/ml streptomycin, 1 ml/L gentamicin and 250 µg/ml 
fungizone, 1X non-essential amino acids and 1.5g/l 
sodium bicarbonate in 95% humidified atmosphere 
containing 5% CO2 at 37 oC. Cells were harvested by 
using 0.25% trypsin in 1mM EDTA for five minutes at 
37oC.
LPS stimulation and GSK-3 inhibition
BV-2 cells were stimulated with LPS (1 µg/ml) and treated 
with either 10 mM LiCl, 10 µM SB216763, 5 µM NP12 
or 10 µM CHIR99021 followed by 24 hours incubation. 
Griess assay
In the cell culture medium concentration of nitrite 
was used as a measure of NO production. Cell culture 
supernatants were collected after 24 hours incubation 
(under designated conditions) and combined with the 
equal volume of freshly prepared Griess reagent (1% 
sulphanilamide and 0.1% N-1-naphthylenediamine 
hydrochloride in 2.5% phosphoric acid) in a 96-well 
plate. After rested for 10 minutes at room temperature, 
absorbance was measured at 530 nm using microplate 
reader (Dynex MRX II). Concentration of nitrite was 
quantitated based on the nitrite standard curve (25).
Glutamate assay
The concentration of glutamate produced by BV-2 cells 
under designated conditions in supplemented culture 
medium was measured according to manufacturer’s 
protocol (Sigma). The absorbance was measured at 450 
nm using microplate reader (Dynex MRX II) and the 
concentration of glutamate was calculated based on the 
generated glutamate standard curve.
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Western blot
BV-2 cells were harvested and lysed with sample buffer 
containing 62.5 mM Tris, 2% SDS, 10% glycerol and 
0.0155 g/ml dithiotretol. Electrophoresis was performed 
on the SDS-PAGE and proteins were transferred to PVDF 
membrane (Milipore Billerica, MA). The membrane 
was stained with the primary antibody of total GSK-3β, 
phospho-GSK-3β (Ser9) or Tubulin at 1:2000 dilution 
overnight at 4oC, followed by horseradish peroxidase 
conjugated secondary antibodies (1:10000 dilution) 
at room temperature for one hour. The bands were 
visualised using chemiluminescent reagent (Pierce 
Biotechnology Inc., Rockford, IL), captured using 
fluorchem imager (Alpha Innotech Corp, San Leandro, 
CA) and quantified using densitometry with labworks 
analysis software (UVP).
Expression of CD200R by Flow cytometry
A total of 5x105 BV-2 cells from each designated 
conditions were stained with 2µg/ml CD200R-PE surface 
antibody for 30 minutes at 4oC. The cells were acquired 
on LSRII Fortessa (BD Biosciences, USA) attached with 
FACSDiva software followed by data analysis using 
FCAP Array software.   
Cytometric Bead Array (CBA)
Cytokine levels produced by BV-2 cells were measured 
using CBA Mouse Inflammation kit (Cat. No: 552364) 
according to manufacturer’s protocol (BD Biosciences, 
USA). Cell supernatants were incubated for 2 hours 
in dark and at room temperature with capture beads 
conjugated with specific antibody for IL-6, IL-12, 
MCP-1 and TNF-α. Detection reagent consisting of 
phycoerythrin (PE) conjugated antibodies were then 
added into each tube. Beads were acquired using flow 
cytometer LSRII Fortessa (BD Biosciences, USA) attached 
with FACSDiva software followed by data analysis using 
FCAP Array software.   
Statistical analysis
Data was presented as mean ± SD with significant 
changes indicated by * (p < 0.05) and ** (p < 0.01). 
Statistical analysis was performed with nonparametric 
Mann Whitney test and Student’s t-test.
RESULTS
LPS increased production of NO in BV-2 cells 
Consistent with previous findings, microglial activation 
induced by LPS can promote NO production (20,26). 
Our data have shown that a substantial amount of 
NO was produced from LPS-stimulated microglia in 
a dose-dependent manner (Figure 1). The moderate 
concentration of LPS (1 µg/ml) was opted for the 
subsequent experiment with BV-2 cells due to its ability 
to induce sufficient amounts of NO (54.85 ± 3.92 µM).
Inhibition of GSK-3 increased phosphorylation of GSK-
3β (Ser9) in BV-2 cells 
GSK-3 is ubiquitously expressed in many cells including 
microglia (27). Increased phosphorylation of GSK-3 has 
been shown to inhibit glycogen synthase activity (28). 
To determine the role of GSK-3 in microglia, BV-2 cells 
were cultured with GSK-3 inhibitor in the absence or 
presence of LPS. The expression of total GSK-3β was 
remained unchanged in all six different conditions 
(Figure 2), indicating that the inhibition of GSK-3 did 
not affect GSK-3β protein level. On the other hand, low 
expression of phospho-GSK-3β at Serine 9 (Ser9) residue 
in the presence or absence of LPS alone was observed 
as compared to those treated with GSK-3 inhibitors, 
which induced higher levels of phospho-GSK-3β (Ser9) 
expression. This finding suggests that activation of GSK-
3 in microglia was inhibited in the presence of GSK-
3 inhibitor through phosphorylation of GSK-3β (Ser9). 
Fig. 1. LPS increased NO production in BV-2 cells. 
Cells were cultured in the presence of LPS at various 
concentrations (0 to 2 µg/ml). Following 24 hours in culture, 
supernatants were collected and the levels of NO were 
determined by Griess assay. Data represent the means from 
three independent experiments performed in triplicates. 
Values are shown in mean ± SD from three independent 
experiments; Mann-Whitney test was conducted to compare 
mean. Statistical significance accepted at p<0.05. 
Fig. 2. Inhibition of GSK-3 increased phosphorylation of GSK-
3β (Ser9) in BV-2 cells. 
Immunoblot analysis of protein levels of total GSK-3β, 
phospho-GSK-3β (Ser9) and Tubulin in the BV-2 cells that 
were previously treated with 10 mM LiCl, 10µM SB216763, 5 
µM NP12 or 10 µM CHIR99021 for 24 hours in the presence 
or absence of 1µg/ml LPS. Data shown are representative of 
three independent experiments.
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Fig. 3. GSK-3 inhibitor increased expression of CD200R. Histogram overlay showing CD200R-PE Mean Fluorescence 
Intensity (MFI) of BV-2 cells that were previously treated with 10 mM LiCl, 10µM SB216763, 5 µM NP12 or 10 µM 
CHIR99021 in the presence or absence of 1µg/ml LPS. Values within histograms correspond to MFI ± SD of the 
corresponding BV-2 cells, n= 3. Statistical differences are indicated by asterisks **p < 0.01; *p < 0.05; Student’s t-test. 
Results are a representative of three independent experiments
This inhibitory action of GSK-3 inhibitors may reduce 
GSK-3β activity without diminishing the amount of 
protein which has been shown by total GSK-3β. 
GSK-3 inhibitor attenuated microglial activation 
through increased expression of CD200R 
Microglial activation status following GSK-3 inhibition 
was determined by expression of CD200R. Increased 
expression of CD200R indicates the inhibition of 
microglial activities by the GSK-3 inhibitor. Results in 
Figure 3 shows that stimulation of microglia by LPS does 
not significantly increase median fluorescence index 
(MFI) of CD200R as compared to unstimulated cells. 
The MFI of LPS stimulated cells was only 0.1 ± 0.2. 
However, the presence of GSK-3 inhibitor marginally 
increased MFI of CD200R. Briefly, LiCl treatment 
increased MFI up to 81.6 ± 10.12, followed by NP12 
(64.3 ± 8.22), CHIR99021 (31.5 ± 6.38) and SB216763 
(10.6 ± 4.08). These findings suggest that activation of 
microglia by LPS stimulation could be revoked by the 
presence of GSK-3 inhibitors.  
Inhibition of GSK-3 reduced NO production in BV-2 
cells 
GSK-3 inhibitors were able to diminish NO production 
in microglia that previously stimulated with LPS. Figure 
4 demonstrates that low level (0.89 ± 0.22 µM) of 
NO was produced by microglia during resting state. 
However, activation of microglia in response to LPS 
produced substantial amount (54.85 ± 3.92 µM) of 
NO. Interestingly, treatment of these cells with GSK-
3 inhibitors significantly reduced the amount of NO. 
CHIR99021 has been shown to be the most potent 
inhibitor in reducing NO levels to 11.41 ± 2.74 µM, 
followed by LiCl (15.24 ± 1.83 µM), NP12 (20.95 ± 
3.72 µM) and SB216763 (27.87 ± 11 µM). These results 
reveal that inhibition of GSK-3 potentially reduced NO 
production in activated microglia.
Inhibition of GSK-3 reduced glutamate production in 
BV-2 cells 
Low level of glutamate produced by resting microglia 
was increased substantially by stimulation of the cells 
with LPS (43.35 ± 2.38 ng/µl). However, high level 
of glutamate produced by stimulated microglia was 
significantly reduced in the presence of GSK-3 inhibitors 
(Figure 5). LiCl has been shown to be the most potent 
inhibitor in reducing glutamate production to 15.54 
± 1.33 ng/µl, followed by NP12 (17.07 ± 1.4 ng/µl), 
CHIR99021 (19.31 ± 1.47 ng/µl) and SB216763 (25.75 ± 
1.81 ng/µl).  These results suggest that all selective GSK-
3 inhibitors potentially reduced glutamate production in 
the activated microglia.
Inhibition of GSK-3 reduced pro-inflammatory cytokine 
levels but increased IL-10 production in BV-2 cells
In order to determine cytokine secretion in microglia, 
the culture supernatant of GSK-3 inhibitor-treated or 
Mal J Med Health Sci 13(1): 1-8, Jan 2017 5
untreated BV-2 cells was collected and the cytokine 
assay was performed using CBA. Results in Figure 6 show 
unstimulated BV-2 cells produced negligible amounts of 
pro-inflammatory mediators. Upon stimulation with LPS, 
production of pro-inflammatory cytokines including IL-6 
and TNF-α, as well as a chemokine, MCP-1, increased 
to 373.38 ± 74.94 pg/ml, 2817.57 ± 1509.58 pg/ml and 
Fig. 4. Inhibition of GSK-3 reduced NO production in BV-2 
cells. 
BV-2 cell lines (3 × 105 cells) were treated with 10 mM LiCl, 
10µM SB216763, 5 µM NP12 or 10 µM CHIR99021 in the 
presence or absence of 1µg/ml LPS for 24 hours. Levels of NO 
in the cell culture supernatants were determined by Griess 
assay. Values are shown in mean ± SD from three independent 
experiments; Mann-Whitney test was conducted to compare 
mean. Statistical significance accepted at p<0.05. 
Fig. 5. Inhibition of GSK-3 reduced glutamate production in 
BV-2 cells. 
BV-2 cell lines (3 × 105 cells) were treated with 10 mM LiCl, 
10µM SB216763, 5 µM NP12 or 10 µM CHIR99021 in the 
presence or absence of 1µg/ml LPS for 24 hours. Levels of 
glutamate in te cell culture supernatants were determined 
by glutamate assay. Values are shown in mean ± SD from 
three independent experiments; Mann-Whitney test was 
conducted to compare mean. Statistical significance accepted 
at p<0.05. Data shown are representative of three independent 
experiments.
Fig. 6. Inhibition of GSK-3 reduced pro-inflammatory cytokine levels but increased IL-10 production in BV-2 cells. BV-2 cell 
lines (3 × 105 cells) were treated with 10 mM LiCl, 10µM SB216763, 5 µM NP12 or 10 µM CHIR99021 in the presence or 
absence of 1µg/ml LPS for 24 hours. Levels of secreted cytokines and chemokine in the cell culture supernatants were determined 
by CBA. Values are shown in mean ± SD from three independent experiments; Mann-Whitney test was conducted to compare 
mean. Statistical significance accepted at p<0.05. Data shown are representative of three independent experiments.
9460.81 ± 2529.46 pg/ml respectively. On the other 
hand, BV-2 cells treated with LiCl potently reduced IL-6 
level to 179.83 ± 33.92 pg/ml and TNF-α level to 1154.31 
± 426.73 pg/ml, whereas NP12 potently reduced the 
MCP-1 level to 3402.43 ± 1476.84 pg/ml. Interestingly, 
reduction of all pro-inflammatory mediators by GSK-3 
inhibitor has coincided with increased in the production 
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of IL-10 up to 212.63 ± 24.08 pg/ml as compared to 
unstimulated BV-2 cells (10.45 ± 4.12 pg/ml). 
DISCUSSION
This study discovers the effects of GSK-3 inhibition 
on the inflammatory mediators in LPS-stimulated 
microglial activation. Activation of microglia can be 
beneficial and crucial in response toward injury that 
occurs in the CNS parenchyma (29). However, chronic 
activation of microglia has been considered a hallmark 
in the pathogenesis of various neurodegenerative 
diseases by the presence of activated microglia at sites 
of injury or plaques in the neurodegenerative CNS (30). 
Various neurotoxins secreted by activated microglia are 
perceived to contribute to neuronal death and eventual 
brain injury (30). Therefore, modulating the activation 
of microglia could be pivotal in limiting inflammation 
and tissue damage within the CNS. One of the potential 
strategies to reduce inflammation in microglia is through 
inhibition of GSK-3. It has been shown that attenuation 
of microglial activation by GSK-3 inhibitor could limit 
the cell migration, reduce secretion of inflammatory 
cytokines and protect the host from inflammation-
induced neurotoxicity (18). Similarly, previous findings 
have also shown that LPS-mediated inflammatory action 
in microglia can be prevented by the presence of GSK-
3 inhibitor (31). Several selective GSK-3 inhibitors 
(LiCl, NP12, SB216763 or CHIR99021) were chosen 
in order to block the activation of microglia through 
inactivation of GSK-3. MTS assay was performed on 
BV-2 cells with each GSK-3 inhibitors at 10 times higher 
than the regularly tested concentration to determine 
the cytotoxicity (data not shown). Interestingly, BV-2 
cells remained intact with approximately 95% survival. 
Among all inhibitors tested in this study, we discovered 
that LiCl and NP-12 are the most potent inhibitors to 
inhibit GSK-3 signalling and the efficacy of these 
inhibitors strongly affirmed in the inhibition of microglial 
activity, attenuation of pro-inflammatory mediators but, 
enhanced IL-10 production. 
 
CD200R is a microglial inhibitory marker that has 
been used to study the microglial activation status. 
Reduction of CD200R expression indicates activation of 
microglia. Our data showed that expression of CD200R 
in microglia had increased following the treatment with 
GSK-3 inhibitor. It suggests that the inhibitory signal 
induced by CD200R was enhanced through blocking 
of GSK-3 signaling in the LPS-mediated microglial 
activation. We had also found that GSK-3 inhibitors 
have the ability to inhibit GSK-3 signaling molecule 
through increased phosphorylation of GSK-3β (Ser9) 
levels in LPS-stimulated BV-2 cells. Inhibition of GSK-
3 through phosphorylation of GSK-3β (Ser9) may exert 
the protective effect of microglia through blocking of 
TLR4 expression (24). Previous findings by Martin and 
colleagues in 2005 have shown that inhibition of TLR4 
expression promotes phosphorylation of GSK-3β, which 
inactivates GSK-3β in microglia (24). These results 
suggest that inhibition of GSK-3 blocked LPS-induced 
microglial activation through increased phosphorylation 
of GSK-3β (Ser9) and expression of CD200R.
 
One of the potential roles of GSK-3 inhibitor is their 
ability to downregulate pro-inflammatory components 
in microglia during inflammation induced by LPS. 
However, the mechanism of GSK-3-mediating 
downregulation of inflammatory cytokine is still unclear. 
Phosphorylation of GSK-3β has been discovered to 
increase IL-10 production with a significant reduction 
of pro-inflammatory cytokines (24). Our present data 
showed that activation of microglia by LPS induced 
production of several pro-inflammatory mediators, 
including NO, glutamate, pro-inflammatory cytokines 
(IL-6 and TNF-α), and the chemokine MCP-1. However, 
increase phosphorylation of GSK-3β by selective GSK-3 
inhibitors was able to diminish the production of all these 
pro-inflammatory components. Conversely, inhibition 
of GSK-3 activity had induced the production of IL-
10. Similar findings in Huang et al., 2009 have shown 
that inhibition of GSK-3 in LPS-stimulated microglia 
decreased the production of NO, but upregulate IL-10 
levels (20). However, these studies did not correlate the 
effects of IL-10 production with other pro-inflammatory 
cytokines. Interestingly, our data had revealed that 
reduction of inflammatory components through 
inhibition of GSK-3 has coincided with the upregulation 
of IL-10 secretion in BV-2 cells. This finding suggests that 
IL-10 could play a significant role to dampen down the 
LPS-mediated pro-inflammatory response in microglia. 
Moreover, it has been investigated that increased IL-10 
levels could limit the immune response to pathogens 
and prevent damage to the host (32). Thus, reduction 
of pro-inflammatory mediators through GSK-3 inhibition 
may be associated with inactivation of microglia and IL-
10 production and could be a strategy in amelioration of 
CNS inflammation. 
CONCLUSIONS
Inhibition of GSK-3 may be a crucial strategy to reduce 
inflammation in the CNS through the production of 
IL-10. The capability of GSK-3 inhibitor to inactivate 
microglia and subsequently reduced in pro-inflammatory 
mediators, demonstrates the possibility of utilising it as 
a treatment to deal with neuroinflammation. However, 
the involvement of IL-10 in the downregulation of 
neuroinflammation remains unclear. Thus, the role of 
IL-10 in microglia-mediated neuroinflammation could 
be further determined by the studies of IL-10-knockout 
mouse model to confirm the effects of GSK-3 inhibition 
on the pro-inflammatory mediators.
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